Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
379 studies found for:    "HIV Seronegativity" [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
"HIV Seronegativity" [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed HIV Incidence and Participation Retention in Pune, India
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
2 Completed Carotid Artery Thickness in HIV Infected and Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity;   Atherosclerosis
Intervention:
3 Completed A Blood Test to Look at Cells of the Immune System in Healthy Children
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
4 Completed ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1;   Biological: ALVAC(2)120(B,MN)GNP (vCP1452) placebo;   Biological: MN rgp120/HIV-1  placebo
5 Completed A Study of Immune System Activity in Healthy Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
6 Completed A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203);   Biological: Aluminum hydroxide;   Biological: MF59;   Biological: rgp120/HIV-1MN
7 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (Immuno-AG)
8 Completed Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC(2)120(B,MN)GNP (vCP1452)
9 Completed Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Lipopeptides LIPO-4
10 Completed A Study of GENEVAX-HIV, a Possible Vaccine
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: APL 400-003
11 Completed A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
Conditions: HIV Infections;   HIV Seronegativity;   Herpes Genitalis
Interventions: Drug: Acyclovir;   Drug: Acyclovir placebo
12 Completed Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: APL 400-003
13 Completed HIV-1 Vaccine Test in Uninfected Adult Volunteers
Conditions: HIV Seronegativity;   AIDS Vaccines
Intervention: Drug: VRC-HIVDNA009-00-VP
14 Completed Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
15 Completed HIV-1 Vaccine Test in Uninfected Adult Volunteers
Conditions: Healthy;   HIV Seronegativity
Intervention: Drug: VRC4302
16 Completed A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV MN120TMG (vCP205)
17 Completed A Study to Test the Safety of Three Experimental HIV Vaccines
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: HIV p24/MF59 Vaccine;   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
18 Completed A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: gp160 MN/LAI-2;   Biological: ALVAC-HIV MN120TMG (vCP205)
19 Unknown  HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV MN120TMG (vCP205)
20 Completed Screening Protocol for HIV Vaccine Studies
Conditions: HIV Seronegativity;   HIV Infections
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years